Stock Movers Corcept Therapeutic Soars, Abbott Labs Sinks, Arista Networks Jumps on AI Spending
Jan 22, 2026
Carmen Reinke, a Bloomberg reporter known for her market insights, shares intriguing developments in the stock market. Corcept Therapeutics impresses with a successful cancer trial, reducing death risk by 35%. Meanwhile, Abbott Labs struggles, forecasting disappointing earnings amidst missed sales expectations. On a high note, Arista Networks thrives with over 370% growth, fueled by AI spending and market upgrades. Carmen's analysis provides a captivating snapshot of today’s stock movers.
AI Snips
Chapters
Transcript
Episode notes
Corcept's Trial Delivers Major Survival Signal
- Corcept's Phase 3 trial showed a 35% reduction in death risk versus chemo alone in platinum-resistant ovarian cancer.
- The FDA is reviewing the new drug application with a target decision in July, spurring a 15% stock jump.
Stock Rebound After Prior FDA Setback
- Corcept's stock had previously plunged after an FDA rejection for a different indication, so today's move is a partial rebound.
- Shares remain below prior highs despite the strong new trial outcome, indicating cautious investor sentiment.
Abbott Misses Estimates And Lowers Guidance
- Abbott reported Q4 organic sales and gave Q1 earnings guidance that missed expectations, triggering a 7% drop in the S&P.
- The company cited discounts on nutrition products aimed at price-sensitive consumers and lingering COVID-test tailwinds as pressures.